Atrial fibrillation and thromboprophylaxis in heart failure: the need for patient-centered approaches to address adherence

trial fibrillation and thromboprophylaxis in heart failure: the need for patient-centered approaches to address adherence Review (1633) Total Article Views Authors: Ferguson C, Inglis SC, Newton PJ, Middleton S, Macdonald PS, Davidson PM Published Date January 2013 Volume 2013:9 Pages 3 - 11 DOI: http://dx.doi.org/10.2147/VHRM.S39571 Received: 25 October 2012 Accepted: 10 December 2012 Published: 18 January 2013 Caleb Ferguson,1 Sally C Inglis,1 Phillip J Newton,1 Sandy Middleton,2,3 Peter S Macdonald,3,4 Patricia M Davidson1,3 1Center for Cardiovascular and Chronic Care, University of Technology, 2National Center for Clinical Outcomes Research (NaCCOR), Australian Catholic University, 3St Vincent's Hospital, Darlinghurst, Sydney, Australia; 4Victor Chang Cardiac Research Institute, University of New South Wales, Sydney, Australia Abstract: Atrial fibrillation is a common arrhythmia in heart failure and a risk factor for stroke. Risk assessment tools can assist clinicians with decision making in the allocation of thromboprophylaxis. This review provides an overview of current validated risk assessment tools for atrial fibrillation and emphasizes the importance of tailoring individual risk and the importance of weighing the benefits of treatment. Further, this review provides details of innovative and patient-centered methods for ensuring optimal adherence to prescribed therapy. Prior to initiating oral anticoagulant therapy, a comprehensive risk assessment should include evaluation of associated cardiogeriatric conditions, potential for adherence to prescribed therapy, frailty, and functional and cognitive ability.